ストックスクリーナーアプリを入手
6.045
1.15%
0.085
Verastem Inc (VSTM) 最新ニュース
MSN Money - MSN
Earnings Preview: Verastem to Report Financial Results on May 07 - Moomoo
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer - BioSpace
Verastem (VSTM) Launches Campaign for Recurrent Low-Grade Serous Ovarian Cancer - GuruFocus
KRAS-mutated LGSOC campaign debuts as Verastem, Inc. targets patient support - Traders Union
Verastem (VSTM) Projected to Post Earnings on Thursday - MarketBeat
Mizuho Securities Adjusts Verastem Price Target to $16 From $18, Maintains Outperform Rating - marketscreener.com
CapEx per share of Verastem, Inc. – MUN:2VSA - TradingView
Verastem to Present at the 8th Annual JMP Securities Healthcare Conference - AOL.com
Liquidity Mapping Around (VSTM) Price Events - Stock Traders Daily
Verastem Oncology announces management changes - MSN
VSTM Price Today: Verastem, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Verastem, Inc. (NASDAQ:VSTM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
VSTM Reiterated by BTIG -- Price Target Maintained at $19.00 - GuruFocus
Torray Investment Partners LLC Purchases Shares of 216,387 Verastem, Inc. $VSTM - MarketBeat
Verastem, Inc. sets first quarter earnings call for May 7 at 4:30pm ET - Traders Union
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 - ChartMill
VSTM Technical Analysis | Trend, Signals & Chart Patterns | VERASTEM INC (NASDAQ:VSTM) - ChartMill
Verastem Inc stock (US92335V1008): Is its oncology pipeline strong enough to unlock biotech upside? - AD HOC NEWS
BTIG Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Verastem's (VSTM) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Verastem (NASDAQ:VSTM) Trading Down 4.1%Here's Why - MarketBeat
Verastem (VSTM) Stock Growth Drivers (Momentum Fading) 2026-04-20Retail Trader Ideas - Cổng thông tin điện tử tỉnh Lào Cai
Vectoring In On Verastem (NASDAQ:VSTM) - Seeking Alpha
Verastem Inc stock (US92335V1008): Is its cancer therapy pipeline strong enough to unlock new upside - AD HOC NEWS
Verastem (VSTM) Stock: Cheap or Expensive (+3.79%) 2026-04-18Social Trade Signals - Cổng thông tin điện tử tỉnh Lào Cai
Verastem (VSTM) Stock: Is It a Strong Buy? (Extends Gains) 2026-04-18Trend Analysis - Cổng thông tin điện tử tỉnh Lào Cai
Verastem, Inc. (VSTM) Stock Analysis: 158% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
VSTM Stock Chart | VERASTEM INC (NASDAQ:VSTM) - ChartMill
Why (VSTM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Q4 2025 Verastem Inc Earnings Call Transcript - GuruFocus
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results - Eastern Progress
PI3K Inhibitor Drug Class Market (2026-2033) | PI3Kα, PI3Kβ, - openPR.com
Chipmakers Recap: How is Verastem Inc managing supply chain issues2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn
Verastem (NASDAQ:VSTM) Trading Up 7.6%What's Next? - MarketBeat
Aug Wrap: What analysts say about Verastem Inc stock2026 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
H.C. Wainwright reiterates Verastem stock rating on durable trial data By Investing.com - Investing.com Canada
Is momentum building in Verastem (VSTM) Stock | Price at $5.63, Up 6.03%Trade Ideas - UBND thành phố Hải Phòng
Sentiment Recap: What analysts say about Verastem Inc stockTrade Entry Report & AI Optimized Trade Strategies - baoquankhu1.vn
Verastem Oncology’s combo shows two-year durability in ovarian cancer - MSN
Fed Meeting: What is the Moat Score of Verastem IncQuarterly Earnings Report & Consistent Income Trade Recommendations - baoquankhu1.vn
Today's Analyst Rating Data for VSTM: Maintained Buy Rating | VS - GuruFocus
Today's Analyst Rating for VSTM: Maintains Buy Rating at $18.00 | VSTM Stock News - GuruFocus
Today's Analyst Rating for VSTM: Maintains Buy Rating at $18.00 - GuruFocus
Verastem stock maintains Buy rating at BTIG on durable trial data - Investing.com Canada
Verastem (NASDAQ:VSTM) Earns "Buy" Rating from BTIG Research - MarketBeat
Verastem (VSTM) Presents Positive Two-Year Data for Ovarian Canc - GuruFocus
Verastem’s cancer drug combo shows durability in 2-year data By Investing.com - Investing.com India
Verastem’s cancer drug combo shows durability in 2-year data - Investing.com
Verastem Oncology announces two-year median follow-up data on Avmapki® Fakzynja® combination therapy - marketscreener.com
Verastem Oncology Announces Two-Year Median Follow-Up Data On Avmapki® Fakzynja® Combination Therapy - TradingView
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s C - Business Wire
Weekly Trades: What analysts say about Verastem Inc stockCEO Change & Weekly High Potential Alerts - baoquankhu1.vn
0.78%
3.01%
大文字化:
|
ボリューム (24 時間):